A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity
Fanying Meng(Shanghai University), Charles P. Hart(University of Auckland), Xiaohong Cai(Wenzhou Medical University)
Cited by 29
Related Papers
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
|Molecular Cancer Therapeutics|2011|206
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL
|Clinical Cancer Research|2019|53
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
|Cancer Biology & Therapy|2015|51
Potent Antitubulin Tumor Cell Cytotoxins Based on 3-Aroyl Indazoles
|Journal of Medicinal Chemistry|2007|50